Other · developed by vTv Therapeutics
GK1-399 is an orally administered agent studied in patients with type 2 diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01474083 | Phase 1/2 | Type 2 Diabetes Mellitus | Completed | VTVT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Type 2 Diabetes Mellitus
Updated Nov 1, 2026. Something wrong or missing? Report it on the VTVT page.
See VTVT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VTVT catalysts and pipeline →